KYKOF - Kyowa Kirin Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD

Kyowa Kirin Co., Ltd.

Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees5,982

Key executives

NameTitlePayExercisedYear born
Mr. Masashi Miyamoto Ph.D.Pres, CEO & Representative Director926.99kN/A1959
Mr. Yutaka Osawa M.B.A.CCO & Representative Director560.51kN/A1959
Mr. Motohiko KawaguchiCFO & Head of Global Fin.N/AN/AN/A
Kazuki NemotoHead of Global LegalN/AN/AN/A
Satoko Yoshida M.B.A.Head of Global Corp. CommunicationsN/AN/AN/A
Hiroshi SonekawaHead of Japan Sales & MarketingN/AN/AN/A
Wataru Murata M.B.A.Chief People Officer & Head of Global HRN/AN/AN/A
Takeyoshi Yamashita Ph.D.Chief Medical Officer Sr., Sr. Managing Exec. Officer & DirectorN/AN/AN/A
Yasuo Fujii M.B.A.Chief Strategy Officer, VP & Managing Exec. Officer,N/AN/AN/A
Jean-David Rafizadeh-Kabe J.D., M.D.Head of Global PharmacovigilanceN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Corporate governance

Kyowa Kirin Co., Ltd.’s ISS governance QualityScore as of 1 June 2023 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.